Jazz Pharmaceuticals, Inc.
Veridion Score
Composite trend over time
Why is JAZZ moving today?
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for JAZZ.
JAZZ insider activity
Jazz Pharmaceuticals, Inc.
3 insiders bought in the last 90 days
Net selling: -$42.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | 2026-06-15 | Smith Mark Douglas | Insider | sell | $230.55 | 1,157 | 9,680 | $267K | SEC Form 4 |
| 2026-06-12 | 2026-06-10 | Patil Neena M | Insider | sell | $231.83 | 1,200 | 51,549 | $278K | SEC Form 4 |
| 2026-06-03 | 2026-06-01 | COZADD BRUCE C | Insider | sell | $235.12 | 6,000 | 372,682 | $1.4M | SEC Form 4 |
| 2026-06-01 | 2026-05-28 | Pearce Samantha | Insider | sell | $235.41 | 6,907 | 50,272 | $1.6M | SEC Form 4 |
| 2026-06-01 | 2026-05-28 | Pearce Samantha | Insider | buy | $109.45 | 6,907 | 57,179 | $756K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 87 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moJAZZ contract awards, year to date.
Public federal awards linked to this ticker.
JAZZ lobbying filings, year to date.
Registered lobbying filings matched to Jazz Pharmaceuticals, Inc..